Home/Pipeline/Parkinson's Program

Parkinson's Program

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Araclon Biotech

About Araclon Biotech

Araclon Biotech, founded in 2004 and based in Zaragoza, Spain, is a Grifols subsidiary dedicated to tackling Alzheimer's Disease through early diagnostics and active immunotherapy. Its core technology platform centers on measuring amyloid-beta peptides (Aβ40 and Aβ42) in blood plasma, providing a less invasive alternative to cerebrospinal fluid or PET imaging for early detection. The company's lead therapeutic candidate, ABvac40, is an active vaccine targeting the Aβ40 peptide, and it has begun preclinical research into Parkinson's disease through a collaboration with the Spanish National Research Council (CSIC). As a fully integrated R&D unit within Grifols, Araclon leverages its parent company's resources while pursuing a high-risk, high-reward strategy in the neurodegenerative disease space.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active